BACKGROUND: Although infection with the human papillomavirus (HPV) is crucial to the development of cervical cancer, it is not considered a sufficient isolated factor to cause this malignancy. The association of the XRCC1 Arg399Gln (rs25487) polymorphism with cervical cancer has been demonstrated in some populations. METHODS: The XRCC1 Arg399Gln genetic variants were identified by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) in patients with advanced cervical cancer (n=189) and controls (n=308). RESULTS: We observed that patients with advanced cervical cancer having the Gln/Gln or Gln/Arg vs Arg/Arg genotype displayed a 1.726-fold increased risk of cervical cancer (95% confidence interval [CI]=1.158-2.572, p=0.007). The odds ratio (OR) for Gln/Gln vs Gln/Arg or Arg/Arg was 1.742 (95% CI=1.073-2.827; p=0.0236). We also found a significantly higher frequency of the XRCC1 399Gln allele in patients with cancer than in controls, with OR=1.489 (95% CI=1.148-1.930, p=0.0026). The p value of the chi-square test for the trend observed for the XRCC1 Arg399Gln polymorphism was also statistically significant (ptrend=0.002). The statistical power of this study amounted to 78% for the Gln/Gln or Gln/Arg genotypes and 61% for the Gln/Gln genotype. CONCLUSION: Although the statistical power of our study did not reach 80%, we found a statistically significant association between the XRCC1 399Gln variant and the incidence of cervical cancer.
BACKGROUND: Although infection with the human papillomavirus (HPV) is crucial to the development of cervical cancer, it is not considered a sufficient isolated factor to cause this malignancy. The association of the XRCC1 Arg399Gln (rs25487) polymorphism with cervical cancer has been demonstrated in some populations. METHODS: The XRCC1 Arg399Gln genetic variants were identified by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) in patients with advanced cervical cancer (n=189) and controls (n=308). RESULTS: We observed that patients with advanced cervical cancer having the Gln/Gln or Gln/Arg vs Arg/Arg genotype displayed a 1.726-fold increased risk of cervical cancer (95% confidence interval [CI]=1.158-2.572, p=0.007). The odds ratio (OR) for Gln/Gln vs Gln/Arg or Arg/Arg was 1.742 (95% CI=1.073-2.827; p=0.0236). We also found a significantly higher frequency of the XRCC1 399Gln allele in patients with cancer than in controls, with OR=1.489 (95% CI=1.148-1.930, p=0.0026). The p value of the chi-square test for the trend observed for the XRCC1 Arg399Gln polymorphism was also statistically significant (ptrend=0.002). The statistical power of this study amounted to 78% for the Gln/Gln or Gln/Arg genotypes and 61% for the Gln/Gln genotype. CONCLUSION: Although the statistical power of our study did not reach 80%, we found a statistically significant association between the XRCC1 399Gln variant and the incidence of cervical cancer.
Authors: Luis Orlando Pérez; Andrea Crivaro; Gisela Barbisan; Lucia Poleri; Carlos Daniel Golijow Journal: Pathol Oncol Res Date: 2013-03-29 Impact factor: 3.201